SCHEDULE 13G: Sio Capital Management Discloses 5.73% Stake in Q32 Bio Inc.

Sio Capital Management, LLC has reported a 5.73% beneficial ownership stake in Q32 Bio Inc., holding 697,413 shares as of December 31, 2024.

Summary

• Sio Capital Management, LLC, a Delaware limited liability company and registered investment adviser, reported beneficial ownership of 697,413 shares of Q32 Bio Inc. common stock.
• This ownership represents 5.73% of Q32 Bio Inc.'s total outstanding common stock.
• The percentage ownership is calculated based on 12,180,701 shares of common stock outstanding as of November 1, 2024, as reported by Q32 Bio Inc. in its Form 10-Q filed on November 7, 2024.
• Sio Capital Management, LLC holds shared voting power and shared dispositive power over all 697,413 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Q32 Bio Inc.

Sentiment

Score: 6

Explanation: Slightly positive, as the disclosure of a significant institutional stake can be viewed favorably by the market, indicating investor confidence, though the filing itself is purely informational.

Positives

• The disclosure of a significant institutional stake (5.73%) by Sio Capital Management, LLC may signal confidence from a professional investment firm in Q32 Bio Inc.'s prospects.

Negatives

• No negative information about Q32 Bio Inc. is contained within this Schedule 13G filing, as it is a disclosure of beneficial ownership.

Risks

• No specific risks related to Q32 Bio Inc.'s operations, financial health, or strategic direction are disclosed in this beneficial ownership filing.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Q32 Bio Inc.'s future performance or strategic direction.

Management Comments

• Sio Capital Management, LLC's Chief Compliance Officer, Jin W. Lee, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock, indicating their passive investment intent. For a biotechnology company like Q32 Bio Inc., attracting institutional investment is a common part of its lifecycle, often signaling increased market interest or validation of its pipeline and strategy.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure required when an entity crosses the 5% beneficial ownership threshold. It does not provide performance metrics or operational results of Q32 Bio Inc. that would allow for a direct comparison to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may positively influence investor sentiment and potentially the stock price.
• Investment Professionals: Provides transparency regarding institutional ownership, which is key for market analysis and investment decisions.

Next Steps

• No specific future actions, events, or milestones for Q32 Bio Inc. are mentioned in this beneficial ownership filing.

Key Dates

Keywords

Q32 Bio Inc., Sio Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Investment Adviser